Why Immunomedics Stock Skyrocketed 125% in April
Shares of biotech Immunomedics (NASDAQ: IMMU) skyrocketed 125% in April, according to data from S&P Global Market Intelligence. The FDA declined to approve the company's TNBC drug in January 2019 because of issues at the manufacturing plant where it was to be produced.